■肿瘤疫苗的开发已成为骨肉瘤(OS)免疫治疗的热门话题;然而,需要鉴定更多具有更强免疫原性的肿瘤抗原。
■我们从在线数据库下载了六组基因表达谱数据。分析了过表达的基因,相交,并用于根据其表达矩阵计算TARGETOS数据集中的免疫浸润丰度。根据潜在的肿瘤抗原基因是否与抗原呈递细胞(APC)表现出高度相关性来鉴定它们。根据ImmPort网站的表达情况,共检索到1330个免疫相关基因(IRGs),并使用共识聚类方法获得OS样本的免疫亚型。预后,免疫微环境,比较了免疫亚型对药物的敏感性。
■总共,680个基因在至少两个数据集中过表达,其中TREM2、TNFRSF12A、和THY1与不同APC呈正相关。基于TARGET-OS中1330个IRG的表达式矩阵,两种免疫亚型,确定了IS1和IS2。IS1亚型的预后优于IS2,IS1亚型患者的免疫检查点(ICP)相关基因表达较高,IS1亚型患者的免疫细胞浸润和对16种药物的敏感性普遍较高。
■我们鉴定了三个APC相关基因,这些基因可以被认为是OS疫苗的潜在新型肿瘤抗原的编码。确定了OS患者中的两种免疫亚型以使用mRNA疫苗实施个性化治疗。
UNASSIGNED: The development of tumor vaccines has become a hot topic in immunotherapy for osteosarcoma (OS); however, more tumor antigens with stronger immunogenicity need to be identified.
UNASSIGNED: We downloaded six sets of gene expression profile data from online databases. The overexpressed genes were analyzed, intersected, and used to calculate the immune infiltration abundance in the TARGET OS dataset based on their expression matrix. Potential tumor antigen genes were identified based on whether they exhibited a high correlation with the antigen-presenting cells (APCs). A total of 1330 immune-related genes (IRGs) from the ImmPort website were retrieved based on their expression, and the Consensus Cluster method was used to obtain immune subtypes of the OS samples. Prognosis, immune microenvironment, and sensitivity to drugs were compared among the immune subtypes.
UNASSIGNED: In total, 680 genes were overexpressed in at least two datasets, of which TREM2, TNFRSF12A, and THY1 were positively correlated with different APCs. Based on the expression matrix of 1330 IRGs in TARGET-OS, two immune subtypes, IS1 and IS2, were identified. The prognosis of the IS1 subtype was better than that of IS2, the expression of immune checkpoint (ICP)-related genes was higher in patients with the IS1 subtype, and immune cell infiltration and sensitivity to 16 drugs were generally higher in IS1 subtype patients.
UNASSIGNED: We identified three APC-correlated genes that can be considered to code for potential novel tumor antigens for OS vaccines. Two immune subtypes in patients with OS were identified to implement personalized treatments using mRNA vaccines.